Zobrazeno 1 - 3
of 3
pro vyhledávání: '"O Odanovic"'
Publikováno v:
Journal of Crohn's and Colitis. 17:i925-i925
Background Vedolizumab (VDZ) is recommended for induction of remissionin patients with inflammatory bowel disease (IBD). Therapeutic drug monitoring (TDM) based on pharmacokinetic measurements of VDZ trough plasma concentrations adds-up on routine pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5232f0017e7a146a17feb8cd2c9a59e4
https://doi.org/10.1093/ecco-jcc/jjac190.0922
https://doi.org/10.1093/ecco-jcc/jjac190.0922
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
T Knezevic, D Cujic, O Odanovic, D Kralj, M Gnjatovic, A Kalaba, D Vrinic Kalem, P Svorcan, S Markovic
Publikováno v:
Journal of Crohn's and Colitis. 16:i349-i349
Background IBD patients, especially on immunosuppressive therapy, are in high-risk of developing infections, the outbreak of the SARS-CoV-2 pandemic, made us approach to the whole situation with special caution. At beginning, we wondered if these pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a53df964af7aef2a1ccc88a370a06ea
https://doi.org/10.1093/ecco-jcc/jjab232.457
https://doi.org/10.1093/ecco-jcc/jjab232.457